title: [Magnetic resonance tomography of focal liver and spleen lesions. Experiences using ferrite, a new RES-specific MR contrast medium].
abstract: Superparamagnetic iron oxide (ferrite), a novel, reticuloendothelial cell-specific contrast agent used for magnetic resonance imaging (MRI), was evaluated in the detection of liver and spleen tumors in animal models and in phase I and II clinical trials in 33 patients. The initial results obtained in experimental cancer models showed a dramatic improvement in tumor detection. Our first clinical trials confirmed the experimental results and showed that ferrite-enhanced MRI significantly (p less than 0.05) increases the detection of individual lesions. Furthermore, the threshold of detectable tumor size decreased significantly, to 3 mm, when standard MR spin echo imaging techniques were used.
authors.affiliation: Department of Radiology, Massachusetts General Hospital, Boston.
authors.forename: E
authors.initials: E
authors.lastname: Rummeny
authors.forename: R
authors.initials: R
authors.lastname: Weissleder
authors.forename: D D
authors.initials: DD
authors.lastname: Stark
authors.forename: G
authors.initials: G
authors.lastname: Elizondo
authors.forename: J T
authors.initials: JT
authors.lastname: Ferrucci
mesh_terms: D000818:Animals; D003287:Contrast Media; D005290:Ferric Compounds; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000556:secondary; D008279:Magnetic Resonance Imaging; D051381:Rats; D013160:Splenic Neoplasms / Q000175:diagnosis*
chemical_list: D003287:Contrast Media; D005290:Ferric Compounds; C001215:ferrite
vernacular_title: Kernspintomographie fokaler Leber- und Milzläsionen. Erfahrungen mit Ferrit, einem neuen RES-spezifischen MR-Kontrastmittel.